Sacituzumab govitecan and pembrolizumab showed a manageable safety profile in PD-L1–positive metastatic TNBC, with lower dose reduction or discontinuation rates than chemotherapy. The combination ...
Zydus Lifesciences Limited (including its subsidiaries and affiliates), an innovation-led life-sciences company, with an ...
Chronic immune-related adverse events occur in more than a third of patients with early-stage TNBC treated with pembrolizumab.
In this study, researchers investigated long-term outcomes from a real-world cohort of patients with stage IV melanoma treated with pembrolizumab following progression on prior therapies.
Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a ...
Preoperative radiation improved T-cell infiltration among patients with hormone receptor-positive, HER2-negative breast ...
3don MSN
Preoperative radiation may improve antitumor immune response in most common form of breast cancer
Preoperative radiation improved T-cell infiltration (TCI) in patients with hormone receptor (HR)-positive, HER2-negative ...
Nadunolimab combined with chemotherapy showed no significant efficacy improvement in metastatic TNBC, despite surpassing ...
News-Medical.Net on MSN
Preoperative radiation may enhance treatment response in patients with HR-positive, HER2-negative breast cancer
Preoperative radiation improved T-cell infiltration (TCI) in patients with hormone receptor (HR)-positive, HER2-negative ...
The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has advised Intas ...
Under the terms of this agreement, Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback